Hepatic Oncology最新文献_第2页

Systematic literature review of trials assessing recommended systemic treatments in hepatocellular carcinoma. 肝细胞癌推荐系统治疗试验的系统文献综述。

IF 1.2

Hepatic Oncology Pub Date : 2021-08-26 eCollection Date: 2022-03-01 DOI: 10.2217/hep-2021-0003

Sarah Ronnebaum, Abdalla Aly, Dipen Patel, Fernando Benavente, Juan-David Rueda

引用次数: 0

Evaluation of tumor mutational burden in small early hepatocellular carcinoma and progressed hepatocellular carcinoma. 早期小肝癌和进展性肝癌肿瘤突变负荷的评价。

IF 5

Hepatic Oncology Pub Date : 2021-08-03 eCollection Date: 2021-12-01 DOI: 10.2217/hep-2020-0034

Mary Wong, Jong T Kim, Brian Cox, Brent K Larson, Stacey Kim, Kevin M Waters, Eric Vail, Maha Guindi

{"title":"Evaluation of tumor mutational burden in small early hepatocellular carcinoma and progressed hepatocellular carcinoma.","authors":"Mary Wong, Jong T Kim, Brian Cox, Brent K Larson, Stacey Kim, Kevin M Waters, Eric Vail, Maha Guindi","doi":"10.2217/hep-2020-0034","DOIUrl":"https://doi.org/10.2217/hep-2020-0034","url":null,"abstract":"While researchers know that tumor mutational burden (TMB) is low in hepatocellular carcinoma (HCC), prior studies have not investigated TMB in cirrhosis, small early HCC and progressed HCC. HCC (n = 18) and cirrhosis (n = 6) cases were identified. TMB was determined by a 1.7 megabase, 409-gene next-generation sequencing panel. TMB values were defined as the number of nonsynonymous variants per megabase of sequence. There was no significant difference between cirrhosis versus small early HCC or between cohorts when stratified by size, early versus progressed, differentiation or morphology. There was a significant difference between cirrhosis and small early HCC versus progressed HCC (p = 0.045), suggesting TMB may be related to HCC progression. TMB similarities in small early HCC and background cirrhosis suggest TMB is not a useful tool for diagnosing small early HCC. Additional study is needed to address TMB in histological and molecular subsets of HCC.","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"8 4","pages":"HEP39"},"PeriodicalIF":5.0,"publicationDate":"2021-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c5/fb/hep-08-39.PMC8577511.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39701720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8

Transarterial chemoembolization alone or followed by bevacizumab for treatment of colorectal liver metastases. 经动脉化疗栓塞单独或随后贝伐单抗治疗结肠直肠癌肝转移。

IF 5

Hepatic Oncology Pub Date : 2021-07-13 eCollection Date: 2022-03-01 DOI: 10.2217/hep-2020-0031

Giammaria Fiorentini, Donatella Sarti, Michele Nardella, Riccardo Inchingolo, Massimiliano Nestola, Alberto Rebonato, Caterina Fiorentini, Camillo Aliberti, Roberto Nani, Stefano Guadagni

{"title":"Transarterial chemoembolization alone or followed by bevacizumab for treatment of colorectal liver metastases.","authors":"Giammaria Fiorentini, Donatella Sarti, Michele Nardella, Riccardo Inchingolo, Massimiliano Nestola, Alberto Rebonato, Caterina Fiorentini, Camillo Aliberti, Roberto Nani, Stefano Guadagni","doi":"10.2217/hep-2020-0031","DOIUrl":"10.2217/hep-2020-0031","url":null,"abstract":"Aims: Bevacizumab (B) in association with systemic chemotherapy is commonly used for the treatment of colorectal cancer liver metastases. The aim of this study was to monitor tumor response, overall survival (OS) and progression-free survival (PFS) of patients with colorectal cancer liver metastases treated with transarterial chemoembolization (TACE) + B compared with TACE alone and to correlate the results with KRAS mutational status.Patients & methods: This was an observational multicentric case-control study (NCT03732235) on the efficacy and safety of B administered after TACE.Results: The disease control rate was significantly higher for the TACE + B than the TACE alone group (p < 0.001). KRAS wild-type patients had a significantly better disease control rate than those with KRAS mutations in the TACE + B group. Median OS and PFS were similar for the TACE + B and TACE groups, whereas median time to progression was significantly higher for the TACE + B group (p < 0.01).Conclusion: The combination of TACE with B may improve tumor response and delay disease progression.","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"9 1","pages":"HEP40"},"PeriodicalIF":5.0,"publicationDate":"2021-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ce/dd/hep-09-40.PMC8577510.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39701722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Unresectable hepatocellular carcinoma treatment with doxorubicin-eluting polyethylene glycol microspheres: a single-center experience. 阿霉素洗脱聚乙二醇微球治疗不可切除的肝细胞癌:单中心经验。

IF 5

Hepatic Oncology Pub Date : 2021-06-04 eCollection Date: 2021-09-01 DOI: 10.2217/hep-2020-0035

Gerardo Tovar-Felice, Andrés García-Gámez, Virgilio Benito-Santamaría, David Balaguer-Paniagua, Jordi Villalba-Auñón, Jaume Sampere-Moragues

{"title":"Unresectable hepatocellular carcinoma treatment with doxorubicin-eluting polyethylene glycol microspheres: a single-center experience.","authors":"Gerardo Tovar-Felice, Andrés García-Gámez, Virgilio Benito-Santamaría, David Balaguer-Paniagua, Jordi Villalba-Auñón, Jaume Sampere-Moragues","doi":"10.2217/hep-2020-0035","DOIUrl":"https://doi.org/10.2217/hep-2020-0035","url":null,"abstract":"Background: Transarterial chemoembolization (TACE) is indicated for unresectable hepatocellular carcinoma.Methods: This was a retrospective study of 50 hepatocellular carcinoma patients treated with TACE using doxorubicin-loaded LifePearl™ to investigate the safety and efficacy of TACE.Results: There was no 30-day mortality, and limited adverse events were reported. At best tumor response, complete response and disease control were 58% and 94%, respectively, with a median of 4.5 months of follow-up. Median overall survival was 33.8 months. Patients with Barcelona Clinic Liver Cancer stage 0 and stage A at best tumor response showed a higher complete response rate (83%) than patients with Barcelona Clinic Liver Cancer stage B (complete response: 50%; p = 0.0414).Conclusion: Doxorubicin-loaded LifePearl™ TACE might be an effective treatment, with a good safety profile, for patients with early/intermediate-stage hepatocellular carcinoma. Further prospective data, especially with a small cohort of selected patients, are required to confirm these results.","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"8 3","pages":"HEP38"},"PeriodicalIF":5.0,"publicationDate":"2021-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/44/5b/hep-08-38.PMC8369521.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39336544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Locoregional therapy patterns and healthcare economic burden of patients with hepatocellular carcinoma in the USA. 美国肝细胞癌患者的局部治疗模式和医疗经济负担

IF 5

Hepatic Oncology Pub Date : 2021-04-21 eCollection Date: 2021-09-01 DOI: 10.2217/hep-2021-0001

Abdalla Aly, Melissa Lingohr-Smith, Jay Lin, Brian Seal

引用次数: 0

A rare histologic subtype of hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma: report of a case. 一种罕见的肝细胞癌的组织学亚型，肉瘤样肝细胞癌:报告1例。

IF 5

Hepatic Oncology Pub Date : 2020-12-29 DOI: 10.2217/hep-2020-0027

Numbereye Numbere, Dongwei Zhang, Diana Agostini-Vulaj

引用次数: 6

Characterizing the mechanism behind the progression of NAFLD to hepatocellular carcinoma. 确定非酒精性脂肪肝发展为肝细胞癌的机制。

IF 1.2

Hepatic Oncology Pub Date : 2020-12-29 DOI: 10.2217/hep-2020-0017

Pierre Nahon, Manon Allaire, Jean-Charles Nault, Valérie Paradis

引用次数: 0

IF 5

Hepatic Oncology Pub Date : 2020-12-29 DOI: 10.2217/hep-2020-0028

Peter D Block, Brianna Shinn, Jin Hyang Kim, Hie-Won Hann

{"title":"Hepatitis B-related hepatocellular carcinoma and stress: untangling the host immune response from clinical outcomes.","authors":"Peter D Block, Brianna Shinn, Jin Hyang Kim, Hie-Won Hann","doi":"10.2217/hep-2020-0028","DOIUrl":"10.2217/hep-2020-0028","url":null,"abstract":"Chronic hepatitis B virus (HBV) infection is a major public health challenge on the global scale. Affecting hundreds of millions worldwide, HBV is a leading risk factor for hepatocellular carcinoma (HCC). Clinical outcomes from chronic HBV infection are varied and appear to be influenced by a complex and dysregulated host immune response. In turn, much attention has been given to the immunologic response to HBV in an effort to identify host factors that lead to the development of HCC. However, the role of nonimmunologic host factors, such as chronic stress, in HBV-related HCC is poorly defined. Indeed, a growing appreciation for the effects of stress on chronic liver diseases raises the question of its role in chronic HBV infection. In this light, the present review will untangle the roles of key host factors in HBV-related HCC with an emphasis on chronic stress as a viable contributor. First discussed is the interplay of stress, inflammation and chronic liver disease. The host immune response's role as a driver of HBV-related HCC is then reviewed, allowing for a close exploration of the effects of stress on immune function in chronic hepatitis B and as a potential risk factor for HBV-related HCC.","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"8 1","pages":"HEP35"},"PeriodicalIF":5.0,"publicationDate":"2020-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8d/59/hep-08-35.PMC7907965.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25453630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Endotrophin, a pro-peptide of Type VI collagen, is a biomarker of survival in cirrhotic patients with hepatocellular carcinoma. 内营养素是 VI 型胶原蛋白的一种原肽，是肝细胞癌肝硬化患者存活率的生物标志物。

IF 5

Hepatic Oncology Pub Date : 2020-12-18 DOI: 10.2217/hep-2020-0030

Diana Julie Leeming, Signe Holm Nielsen, Roslyn Vongsuvanh, Pruthviraj Uchila, Mette Juul Nielsen, Alexander L Reese-Petersen, David van der Poorten, Mohammed Eslam, Detlef Schuppan, Morten Asser Karsdal, Jacob George

{"title":"Endotrophin, a pro-peptide of Type VI collagen, is a biomarker of survival in cirrhotic patients with hepatocellular carcinoma.","authors":"Diana Julie Leeming, Signe Holm Nielsen, Roslyn Vongsuvanh, Pruthviraj Uchila, Mette Juul Nielsen, Alexander L Reese-Petersen, David van der Poorten, Mohammed Eslam, Detlef Schuppan, Morten Asser Karsdal, Jacob George","doi":"10.2217/hep-2020-0030","DOIUrl":"10.2217/hep-2020-0030","url":null,"abstract":"Aim: Type VI collagen, is emerging as a signaling collagen originating from different types of fibroblasts. A specific fragment of Type VI collagen, the pro-peptide, is also known as the hormone endotrophin. We hypothesized that this fibroblast hormone would be of particular relevance in cancer types with a high amount of fibrosis activity, namely for outcome in hepatocellular carcinoma (HCC) cirrhotic patients.Patients & methods: Plasma C6M, PRO-C6 and alphafeto-protein (AFP) were assessed in 309 patients with mixed etiologies (hepatitis C, hepatitis B, alcohol and nonalcoholic fatty liver) diagnosed as cirrhotics, cirrhotics with HCC, noncirrhotics and healthy controls. Progression-free survival and overall survival (OS) data were collected up to 6120 days after diagnosis. The ability of each marker to predict survival was investigated.Results & conclusion: The level of endotrophin assessed by PRO-C6 was able to separate healthy controls, noncirrhotics and cirrhotics from HCC (p < 0.05-0.0001). Both endotrophin and C6M provided value in the prediction of OS in cirrhotic patients with HCC. In the multivariate analysis for identifying HCC, in patients with high endotrophin (highest quartile) and that were positive for AFP (≥20 IU/ml), the hazard ratio for predicting OS was increased from 3.7 (p = 0.0006) to 14.4 (p = 0.0001) when comparing with AFP positive as a stand-alone marker. In conclusion, plasma levels for markers of Type VI collagen remodeling were associated with survival in cirrhotic patients with HCC. A combination of AFP with endotrophin improved the prognostic value compared with AFP alone for predicting OS in cirrhotic patients with HCC.","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"8 2","pages":"HEP32"},"PeriodicalIF":5.0,"publicationDate":"2020-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0a/96/hep-08-32.PMC8162185.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39060450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Balloon-occluded chemoembolization for hepatocellular carcinoma: a prospective study of safety, feasibility and outcomes. 肝细胞癌球囊闭塞化疗栓塞:安全性、可行性和结果的前瞻性研究。

IF 5

Hepatic Oncology Pub Date : 2020-10-13 DOI: 10.2217/hep-2020-0022

Ana-Maria Bucalau, Illario Tancredi, Martina Pezzullo, Raphael Leveque, Simona Picchia, Jean-Luc Van Laethem, Gontran Verset

{"title":"Balloon-occluded chemoembolization for hepatocellular carcinoma: a prospective study of safety, feasibility and outcomes.","authors":"Ana-Maria Bucalau, Illario Tancredi, Martina Pezzullo, Raphael Leveque, Simona Picchia, Jean-Luc Van Laethem, Gontran Verset","doi":"10.2217/hep-2020-0022","DOIUrl":"https://doi.org/10.2217/hep-2020-0022","url":null,"abstract":"Aim: Evaluation of safety and efficacy of selective balloon-occluded transarterial chemoembolization using polyethylene glycol embolizing microspheres in patients with hepatocellular carcinoma.Materials & methods: Twenty-four consecutive patients were included in this monocentric prospective trial. Adverse events were evaluated at 24 h and 1 month. Imaging response according to modified response evaluation criteria in solid tumors was assessed at 1, 3 and 6 months.Results: The median time of follow-up was of 22.8 months (interquartile range (IQR) 17.38-26.22). Clinical grade 1/2 toxicities (0% >grade 2) were reported in 25.7% of patients, with abdominal pain being the most frequent complication (17.1%). No 30-days mortalities or liver decompensation were observed. The 1-month follow-up MRI showed an overall response rate of 74.3%.Conclusion: Balloon-occluded transarterial chemoembolization was shown to be safe and effective.","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"8 1","pages":"HEP31"},"PeriodicalIF":5.0,"publicationDate":"2020-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/hep-2020-0022","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25445417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5